Use of the CYP2E1 genotype and phenotype for the biological monitoring of occupational exposure to styrene

Toxicology Letters

Volumn 192, Issue 1, 2010, Pages 34-39

  Prieto Castello M J ^a   Cardona, A ^a   Marhuenda, D ^a   Roel, J M ^b   Corno, A ^c  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b INVASSAT Alicante ^*  (Spain)

^c Laboratory of Genetic Analysis ANCOR   (Spain)

Author keywords

Buccal swab; Cytochrome P450 2E1; Genotype; Phenotype; Polymorphisms; Styrene

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450 2E1; MANDELIC ACID; MESSENGER RNA; PHENYLGLYOXYLIC ACID; STYRENE;

ADULT; ALLELE; ARTICLE; BIOLOGICAL MONITORING; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; METABOLITE; MOUTH CAVITY; OCCUPATIONAL EXPOSURE; OCCUPATIONAL TOXICOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TOXICOGENETICS; URINALYSIS; URINARY EXCRETION; WILD TYPE;

ADULT; CYTOCHROME P-450 CYP2E1; GENOTYPE; GLYOXYLATES; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PHENOTYPE; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; STYRENE; YOUNG ADULT;

EID: 72949102275     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.01.011     Document Type: Article

References (43)

1. American Conference of Governmental Industrial Hygienists (ACGIH), 2007. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Indices for 2007. ACGIH, Cincinnati, OH.
2. Benowitz N.L., Peng M., and Jacob III P. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin. Pharmacol. Ther. 74 (2003) 468-474
3. Bolt H.M., Roos P.H., and Thier R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processsing of industrial chemicals: consequences for occupational and environmental medicine. Int. Arch. Occup. Environ. Health 76 (2003) 174-185
4. Botto F., Seree E., el Khayari R., de Sousa G., Massacrier A., Placidi M., Cau P., Pellet W., Rahamani R., and Barra Y. Tissue-specific expression and methylationof the human CYP2E1 gene. Biochem. Pharmacol. 48 (1994) 1095-1103
5. Brockmoller J., Cascorbi I., Kerb R., and Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 56 17 (1996) 3915-3925
6. Cai L., Zheng Z.L., and Zhang Z.F. Cytochrome p450 2E1 polymorphisms and the risk of gastric cardia cancer. World J. Gastroenterol. 11 12 (2005) 1867-1871
7. Duan H., Zhang J., Huang P., and Zhang Y. Buccal swab: a convenient source of DNA for analysis of IL-1 gene polymorphisms. Hua. Xi. Kou. Qiang. Yi. Xue. Za. Zhi. 19 1 (2001) 11-13
8. Garte S., Gaspari L., Alexandrie A.K., Ambrosone C., Autrup H., Autrup J.L., Baranova H., Bathum L., Benhamou S., Boffetta P., Bouchardy C., Breskvar K., Brockmoller J., Cascorbi I., Clapper M.L., Coutelle C., Daly A., Dell'Omo M., Dolzan V., Dresler C.M., Fryer A., Haugen A., Hein D.W., Hildesheim A., Hirvonen A., Hsieh L.L., Ingelman-Sundberg M., Kalina I., Kang D., Kihara M., Kiyohara C., Kremers P., Lazarus P., Le Marchand L., Lechner M.C., van Lieshout E.M., London S., Manni J.J., Maugard C.M., Morita S., Nazar-Stewart V., Noda K., Oda Y., Parl F.F., Pastorelli R., Persson I., Peters W.H., Rannug A., Rebbeck T., Risch A., Roelandt L., Romkes M., Ryberg D., Salagovic J., Schoket B., Seidegard J., Shields P.G., Sim E., Sinnet D., Strange R.C., Stucker I., Sugimura H., To-Figueras J., Vineis P., Yu M.C., and Taioli E. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomar. Prev. 10 (2001) 1239-1248
9. Hallier E., Goergens H.W., Karels H., and Golka K. Anote on individual differences in the urinary excretion of optical enantiomers of styrene metabolites and of styrene-derived mercapturic acids in humans. Arch. Toxicol. 69 (1995) 300-305
10. Haufroid V., Buchet J.P., Gardinal S., and Lison D. Cytochrome P4502E1 phenotyping by the measurement of the chloroxazone metabolic ratio: assessment of its usefulness in workers exposed to styrene. Int. Arch. Occup. Environ. Health 75 (2002) 453-458
11. Haufroid V., Buchet J.P., Gardinal S., Ghittori S., Imbriani M., Hirvonen A., and Lison D. Importance of genetic polymorphisms of drug-metabolizing enzymes for the interpretation of biomarkers of exposure to styrene. Biomarkers 6 3 (2001) 236-249
12. Haufroid V., Jakubowski M., Janasik B., Ligocka D., Buchet J.P., Bergamaschi E., and Manini P. Interest of genotyping and phenotyping of drug-metabolizing enzimesfor the interpretations of biological monitoring of exposure to styrene. Pharmacogenetics 12 9 (2002) 691-702
13. Haufroid V., Toubeau F., Clippe A., Buysschaert M., Gala J.L., and Lison D. Real time quantification of cytochrome P45002E1 mRNA in human peripheral blood lymphocytes by reverse transcription-PCR: method and practical application. Clin. Chem. 47 (2001) 1126-1129
14. Hayashi S., Watanabe J., and Kawajiri K. Genetic polymorphism in the 5′ flanking region change transcriptional regulation of the human cytochrome P450IIEI gene. J. Biochem. 110 (1991) 559-565
15. Howard L.A., Micu A.L., Sellers E.M., and Tyndale R.F. Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. J. Pharmacol. Exp. Ther. 299 (2001) 542-550
16. Jenkins S.S., and Fennell T.R. Review of metabolic fate of styrene. Crit. Rev. Toxicol. 24 (1994) S11-33
17. Kim R.B., O'Shea D., and Wilkinson G.R. Interindividual variability of chloroxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin. Pharmacol. Ther. 57 (1995) 645-655
18. Lieber S. Cytochrome P-450E1: its physiological and pathological role. Physiol. Rev. 77 (1997) 517-544
19. -ΔΔCt method. Methods 25 (2001) 402-408
20. Lucas D., Farez C., Bardou L.G., Vaisse J., Attali J.R., and Valensi P. Cytochrome CYP2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fun. Clin. Pharmacol. 12 (1998) 553-558
21. Lucas D., Ferrara R., Gonzales E., Albores A., Manno M., and Berthou F. Cytochrome CYP2E1 phenotyping and genotyping in the evaluation of health risks from exposure to polluted environments. Toxicol. Lett. 124 (2001) 71-81
22. Lucas D., Ferrara R., Gonzales E., Bodenez P., Albores A., Manno M., and Berthou F. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 9 (1999) 377-388
23. Lucas D., Menez C., Girre C., Berthou F., Bodenez P., Joannet I., Hispard E., Bardou L.G., and Menez J.F. Cytochrome P4502E1 genotype and chlorzoxazone metabolism in healthty ans alcoholic Caucasian subjects. Pharmacogenetics 5 (1995) 298-304
24. Ma M., Umemura T., Mori Y., Gong Y., Saijo Y., Sata F., Kawai T., and Kishi R. Influence of genetic polymorphisms of styrene-metabolizing enzymes and smoking habits on levels of urinary metabolites after occupational exposure to styrene. Toxicol. Lett. 160 (2005) 84-91
25. Marhuenda D., Prieto M.J., Periago J.F., Martí J., Perbellini L., and Cardona A. Biological monitoring of styrene exposure and possible interference of acetone co-exposure. Int. Arch. Occup. Environ. Health 69 (1997) 455-460
26. Mostafa A.M., Abdel-Naim A.B., Abo-Salem O., Abdel-Haziz A.H., and Hamada F.M. Renal metabolism of acrylonitrile to cyanide: in vitro studies. Pharmacol. Res. 40 (1999) 195-200
27. Packer B.R., Yeager M., Burdett L., Welch R., Beerman M., Qi L., Sicotte H., Staats B., Acharya M., Crenshaw A., Eckert A., Puri V., Gerhard D., and Chanock S.J. SNP500 cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res. 1 34 (Database issue) (2006) D617-D621
28. Raucy J.L., Curley G., and Carpenter S.P. Use of lymphocytes for assesing ethanol-mediated alterations in the expression of hepatic cytocrrome CYP2E1. Alcohol. -Clin. Exp. Res. 19 (1995) 1369-1375
29. Raucy J.L., Schultz E.D., Wester M.R., Arora S., Johnston D.E., Omdahl J.L., and Carpenter S. Human lymphocyte cytochrome CYP2E1, a putative marker for alcohol mediated changes in hepatic chlorzoxazone activity. Drug Metab. Dispos. 25 (1997) 1429-1435
30. Raunio H., Husgafvel-Pursiainen K., Antilla S., Hietanene E., Hirvonene A., and Pelkonen O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-a review. Gene 159 (1995) 113-121
31. Richards B., Skoletsky J., Shuber A.P., Balfour R., Stern R.C., Dorkin H.L., Parad R.B., Witt D., and Klinger K.W. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum. Mol. Genet. 2 2 (1993) 159-163
32. Sambrok J., and Russell D.W. Molecular Cloning: A Laboratory Manual. 3rd ed. (2001), Cold Spring Harbor Laboratory Press
33. Shimada T., Yamzaki H., Mimura M., Inui Y., and Guenguerich F.P. Interindividual variation s in human liver cytochrome p-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 caucasians. J. Pharmacol. Exp. Ther. 270 (1994) 414-423
34. Steinberg K., Beck J., Nickerson D., Garcia-Closas M., Gallagher M., Caggana M., Reid Y., Cosentino M., Ji J., Johnson D., Hayes R.B., Earley M., Lorey F., Hannon H., Khoury M.J., and Sampson E. DNA banking for epidemiologic studies: a review of currente practices. Epidemiology 13 (2002) 246-254
35. Subramanian U., and Ahmed A.E. Intestinal toxicity of acrylonitrile: in vitro metabolism by intestinal cytochrome P4502E1. Toxicol. Appl. Pharmacol. 135 (1995) 1-8
36. Sumner S.J., and Fennell T.R. Review of the metabolic fate of styrene. Crit. Rev. Toxicol. 24 Suppl. (1994) S11-S33
37. Thier R., Brüning T., Roos P.H., Rihs H.P., Golka K., Ko Y., and Bolt H.M. Markers of genetic susceptibility in human and environmental hygiene and toxicology. Int. J. Hyg. Environ. Health 206 3 (2003) 149-171
38. Uematsu F., Kikuchi H., Motomiya M., Abe T., Sagami I., Ohmachi T., and Wakui A. Association betweeen restriction fragment length polymorphism of the human cytochrome P450 2E1 gene and susceptibility to lung cancer. Jpn. J. Cancer Res. 82 (1991) 254-256
39. Vieira I., Pasanen M., Raunio H., and Cresteil T. Expression of CYP2E1 in human lung and Kidney during development and in full-term placenta: a differential methylation of the gene is involved in the regulation process. Pharmacol. Toxicol. 83 (1998) 183-187
40. Villard P.H., Seree E.M., Re J.L., De Meo M., Barra Y., Attolini L., Dumenil G., Catalin J., Durand A., and Lacarelle B. Effects of tobacco smoke on the gene expression of the Cyp1a, Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung: relation to single strand breaks of DNA. Toxicol. Appl. Pharmacol. 148 (1998) 195-204
41. Watanabe J., Hayashi S., and Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5-flanking region. J. Biochem. (Tokyo) 116 (1994) 321-326
42. Wenker M.A., Kezic S., Monster A.C., and de Wolff F.A. Metabolic capacity and interindividual variation in toxicokinetics of styrene in volunteers. Hum. Exp. Toxicol. 20 (2001) 221-228
43. Wigaeus E., Löf A., Bjurstrom R., and Byfält Nordquist M. Exposure to styrene. Uptake, distribution, metabolism and elimination in man. Scand. J. Work. Environ. Health 9 (1983) 479-488